Amgen Execs to Present at Morgan Stanley Healthcare Conference
Event summary
- Amgen will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
- Jay Bradner, EVP of R&D, AI, and Data, and Thomas Dittrich, EVP and CFO, will lead the presentation.
- The webcast will be available live and archived for at least 90 days post-event.
- Amgen focuses on innovative medicines for cancer, inflammatory conditions, rare diseases, heart disease, and obesity.
The big picture
Amgen's participation in the Morgan Stanley conference underscores its strategic emphasis on innovation and financial transparency. As a key player in the biotech sector, Amgen's presentation will likely focus on its pipeline advancements and financial health, both critical for investors in an increasingly competitive market. The company's inclusion in the Dow Jones Industrial Average and Nasdaq-100 Index highlights its significance in the broader market landscape.
What we're watching
- R&D Strategy
- How Amgen's focus on AI and data will impact its pipeline and competitive positioning.
- Financial Performance
- Whether Amgen can sustain growth amid increasing competition in biotech.
- Market Positioning
- The pace at which Amgen can differentiate itself in the crowded healthcare sector.
Related topics